Can Ozempic help you quit smoking? What the GLP-1 craving research shows (2026)

Why this keeps coming up

One of the most striking things people report on GLP-1 drugs is that they want less of other things too — fewer cigarettes, less alcohol, sometimes less compulsive behavior generally — often without setting out to change them. It's common enough that 'Ozempic and cigarettes' has become a real search trend, and it points to something biological rather than coincidental.

The explanation is that these drugs don't only act on the gut. GLP-1 receptors are also in brain regions that govern reward and motivation, so a drug that dials down food cravings can plausibly dial down the pull of nicotine and alcohol through the same circuitry.

What the evidence actually shows

For nicotine, the current picture is 'promising but preliminary.' Preclinical studies show that activating GLP-1 receptors reduces nicotine's rewarding effects and nicotine-seeking behavior, and early clinical evidence points in the same direction [1]. Reviews of the field now explicitly frame GLP-1 receptor agonists as having therapeutic potential for smoking cessation, while stressing that the definitive trials are still needed [2].

So the honest status is: a real, mechanism-backed signal, supported by animal data and early human observations, but not yet the rigorous, dosed, approved evidence that would make it a standard treatment. That gap between 'promising signal' and 'proven therapy' is the whole story here.

How to read the hype

It's easy to jump from 'GLP-1 might curb cravings' to 'Ozempic is a quit-smoking drug.' Don't. It is not approved for smoking or any addiction, the evidence isn't yet strong enough to prescribe it for that purpose, and it carries real risks and contraindications that only make sense to accept for an approved indication.

If you're already taking a GLP-1 for weight or diabetes and find your cravings drop, enjoy the bonus. But if quitting is the goal, the tools with strong evidence — nicotine replacement, varenicline, and behavioral support for smoking; established treatments for alcohol use disorder — are where to start, ideally with a clinician who can fold in whatever emerges as the GLP-1 research matures.

The bottom line

There's real, mechanism-based early evidence that GLP-1 drugs reduce nicotine (and alcohol) cravings by acting on the brain's reward system, which is why so many users report smoking and drinking less [1][2]. But it's investigational, not an approved addiction treatment, and not a reason to seek the drug for that alone. Treat reduced cravings as a welcome side effect if you're already on it — and use proven cessation tools if quitting is your actual goal.